Data Independent Acquisition Mass Spectrometry Can Identify Circulating Proteins That Predict Future Weight Loss with a Diet and Exercise Programme.
IGR
SWATH MS
lifestyle change
proteomics
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
25 Jan 2019
25 Jan 2019
Historique:
received:
21
12
2018
revised:
22
01
2019
accepted:
23
01
2019
entrez:
30
1
2019
pubmed:
30
1
2019
medline:
30
1
2019
Statut:
epublish
Résumé
We investigated biological determinants that would associate with the response to a diet and weight loss programme in impaired glucose regulation (IGR) people using sequential window acquisition of all theoretical fragment ion spectra (SWATH) mass spectrometry (MS), a data acquisition method which complement traditional mass spectrometry-based proteomics techniques. Ten women and 10 men with IGR underwent anthropometric measurements and fasting blood tests. SWATH MS was carried out with subsequent immunoassay of specific peptide levels. After a six-month intervention, 40% of participants lost 3% or more in weight, 45% of patients remained within 3% of their starting weight and 15% increased their weight by 3% or more. Hemoglobin A1c (HbA1C) level was reduced with weight loss with improvements in insulin sensitivity. SWATH MS on pre-intervention samples and subsequent principal component analysis identified a cluster of proteins associated with future weight loss, including insulin-like growth factor-II (IGF-II) and Vitamin D binding protein. Individuals who lost 3% in weight had significantly higher baseline IGF-II levels than those who did not lose weight. SWATH MS successfully discriminated between individuals who were more likely to lose weight and potentially improve their sensitivity to insulin. A higher IGF-II baseline was predictive of success with weight reduction, suggesting that biological determinants are important in response to weight loss and exercise regimes. This may permit better targeting of interventions to prevent diabetes in the future.
Identifiants
pubmed: 30691056
pii: jcm8020141
doi: 10.3390/jcm8020141
pmc: PMC6406968
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medical Research Council
ID : MR/M008959/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N00583X/1
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Diabetes. 2003 Jun;52(6):1403-8
pubmed: 12765950
Growth Horm IGF Res. 2004 Oct;14(5):337-75
pubmed: 15336229
J Clin Endocrinol Metab. 2005 Dec;90(12):6588-95
pubmed: 16189260
Am J Med. 2006 Feb;119(2):167.e9-15
pubmed: 16443426
J Clin Invest. 2008 Sep;118(9):2992-3002
pubmed: 18769626
FASEB J. 2009 Mar;23(3):709-19
pubmed: 18952711
Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E654-63
pubmed: 19141684
Diabetes. 2010 Jun;59(6):1506-11
pubmed: 20299470
Nutr Metab Cardiovasc Dis. 2012 Mar;22(3):208-14
pubmed: 20951014
Endocrinology. 2011 Jun;152(6):2184-96
pubmed: 21447640
Mol Cell Proteomics. 2012 Jun;11(6):O111.016717
pubmed: 22261725
Regul Pept. 2012 Oct 10;178(1-3):6-10
pubmed: 22387701
Int J Biol Sci. 2013;9(1):16-21
pubmed: 23289013
Obesity (Silver Spring). 2013 Mar;21(3):E182-9
pubmed: 23404948
Cancer Immunol Immunother. 2013 May;62(5):955-65
pubmed: 23564178
Horm Metab Res. 2014 Mar;46(3):224-31
pubmed: 23979787
J Clin Endocrinol Metab. 2014 Jan;99(1):178-83
pubmed: 24170105
Anal Chem. 2014 Jan 21;86(2):1202-9
pubmed: 24383719
Lipids Health Dis. 2014 Jan 15;13:15
pubmed: 24422660
J Clin Endocrinol Metab. 2014 May;99(5):1675-86
pubmed: 24483154
Life Sci. 2014 May 8;103(1):41-8
pubmed: 24631137
Diabetes Metab Syndr Obes. 2014 May 23;7:169-83
pubmed: 24920930
Metabolism. 2014 Aug;63(8):995-9
pubmed: 24929893
Prim Care Diabetes. 2015 Feb;9(1):3-8
pubmed: 25175562
Diabetes Care. 2015 Mar;38(3):431-8
pubmed: 25216510
Diabetes Metab Syndr. 2015 Jan-Mar;9(1):19-23
pubmed: 25450816
Obes Rev. 2015 Feb;16(2):171-86
pubmed: 25494712
Br J Gen Pract. 2015 Sep;65(638):450
pubmed: 26324473
Endocrine. 2017 May;56(2):357-365
pubmed: 27388590
Horm Metab Res. 2017 Jan;49(1):58-63
pubmed: 27589346
Nature. 2016 Sep 14;537(7620):347-55
pubmed: 27629641
Syst Rev. 2017 Mar 20;6(1):57
pubmed: 28320464
MAbs. 2017 May/Jun;9(4):654-663
pubmed: 28346045
Diabetes Obes Metab. 2017 Sep;19(9):1295-1305
pubmed: 28417575
Expert Rev Proteomics. 2017 May;14(5):419-429
pubmed: 28436239
Horm Res Paediatr. 2017;88(5):354-363
pubmed: 28926833
Drug Metab Pharmacokinet. 2018 Apr;33(2):133-140
pubmed: 29610054
J Med Internet Res. 2019 Jan 08;21(1):e298
pubmed: 30622090
JMIR Mhealth Uhealth. 2019 Jan 09;7(1):e11267
pubmed: 30626566
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825